NVCR
NovoCure Ltd.
NASDAQ · Healthcare · Medical - Instruments & Supplies · JE
$14.58
+8.56%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$14.00
From 52W high−27.06%
Volume482845.00
Market cap$1.70B
P/E (TTM)—
P/S (TTM)2.3x
Div yield—
Key dataNov 4, 2026
Open
$14.00
From 52W high
−27.06%
Volume
482845.00
Market cap
$1.70B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−14.1x
P/E (TTM)
—
RSI (14)
46.8
MomentumView details →
1D Return
+8.56%
YTD Return
+10.36%
SummaryUpdated Sep 1, 2026
NovoCure Limited (NASDAQ:NVCR) is a Jersey-incorporated oncology company founded in 2000 that has developed a novel cancer treatment technology called Tumor Treating Fields (TTFields). The company went public in 2015 and has since established itself as a pioneer in delivering electric field therapy for solid tumor cancers. NovoCure operates globally with commercial presence in the United States, Europe, Japan, and other international markets, focusing on bringing its unique non-invasive treatment modality to cancer patients worldwide.
Similar companies
Latest newsMore news →
NovoCure reported third-quarter 2026 revenue of $193.4 million, up 16% year over year, and a net loss of $10.4 million, or $0.09 per diluted share.6d agoNovoCure Ltd announced that it entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate Tumor Treating Fields therapy with chemotherapy and VS-7375 for locally advanced pancreatic cancer.7d ago